Macular Degeneration Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 50 or older at the time of signing consent
• People who are willing and able to give informed consent
• People who are able and willing to attend all scheduled visits and follow all study procedures
• Women who are either unable to become pregnant, or who have a negative pregnancy test at the screening visit and agree to use suitable contraception during the study and for one month after the last dose
• People with a confirmed diagnosis of symptomatic wet age-related macular degeneration (wet AMD), based on specific eye imaging tests (confirm with trial site)
• People whose wet AMD involves certain patterns of abnormal blood vessel growth affecting or near the central part of the retina, with signs of fluid leakage (confirm with trial site)
• People who have never previously been treated for their condition with injections into the eye, laser treatment to the central retina area, or a light-activated therapy called photodynamic therapy
• People whose vision in the study eye falls within a specific range, roughly equivalent to seeing between 20/32 and 20/320 on a standard eye chart

Who may not be able to join:

• People whose abnormal blood vessel growth is caused by something other than typical AMD, such as certain inherited eye conditions, eye injury, severe short-sightedness, or eye inflammation
• People who have active inflammation inside the eye, or a suspected or active infection in or around either eye at the start of the study
• People who have any other eye condition in the study eye that, in the investigator's judgment, could require treatment during the study or limit the potential for vision improvement
• People who have had cataract surgery within 6 months before joining, or who would need cataract surgery during the study
• People who have a specific type of damage to a layer of the retina (called an RPE tear) in the study eye at the start of the study
• People who currently have, or have had in the past 4 weeks, bleeding in the jelly-like substance inside the study eye
• People with a history of a specific type of retinal detachment, a large macular hole (stage 3 or 4), or any retinal break that has not been adequately repaired
• People who have had any of the following procedures in the study eye: a particular type of eye surgery to remove the vitreous gel, light-activated therapy, any eye or vision-correcting surgery within 6 months before the study, corneal transplant, surgery under the retina, or laser treatment to the retina
• People with poorly controlled glaucoma or high eye pressure (above 25 mmHg) in the study eye, even when on medication, or as judged by the investigator
• People who have used steroid medications in or around the study eye for extended periods within the 6 months before the study (specific timeframes apply — confirm with trial site); exceptions exist for low stable doses of certain systemic steroids, and for inhaled, nasal, or skin-applied steroids
• People who have previously had radiation therapy near the study eye
• People who have a medical condition that, in the investigator's judgment, would make it unsafe or impractical for them to complete the study
• People with a known allergy to any ingredient in the study treatment, or a clinically significant sensitivity to certain dyes used in eye imaging
• People who have taken part in another clinical trial of an investigational treatment within 30 days (or longer, depending on the treatment) before the study starts; note that studies involving only over-the-counter vitamins, supplements, or diet are not excluded
• People who have received a systemic (whole-body) anti-VEGF therapy within 90 days before the study starts
• People who have had a stroke or heart attack within 90 days before the study starts
• People with uncontrolled high blood pressure, defined as a reading of 180 mmHg or higher (top number) and/or 100 mmHg or higher (bottom number) at screening

Important: Always verify eligibility with the trial site directly before applying.